Luye Pharma Group (HK:2186) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Luye Pharma Group has announced the inclusion of several innovative drugs, including Ruoxinlin and Baituowei, in China’s 2024 National Reimbursement Drug List. This development is expected to enhance patient access and accelerate commercialization, potentially boosting financial returns for the company. The inclusion marks a significant milestone for Luye’s proprietary antidepressant, Ruoxinlin, as a breakthrough ‘Made-in-China’ drug.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
